Pharmacodynamic effects and functional improvements were observed through nine months post-dosing with a single administration of ISP-001. As of the data cutoff date of September 19, 2024, no adverse events have been reported. Data for ISP-001 for Mucopolysaccharidosis Type I to be presented on October…

SEATTLE–(BUSINESS WIRE)– Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the upcoming WORLDSymposium 2024 Conference, held in San Diego, February 4-9, 2024. WORLDSymposium is the largest international gathering of lysosomal…

SEATTLE–(BUSINESS WIRE)– Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it has successfully closed a license with the Regents of the University of Minnesota for the exclusive, worldwide rights to intellectual property (IP) for…

San Francisco, CA – (BUSINESS WIRE) – January 26, 2023 — Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“Immusoft”), a clinical-stage cell therapy company dedicated to improving the lives of patients with rare or genetic diseases, announced today that the California Institute…

SEATTLE–(BUSINESS WIRE)–Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for ISP-001 in the treatment of MPS I. The open…

Christiane Hampe, Ph.D., Senior Director of Research, will present preclinical data on Immusoft’s Immune System Programming Platform SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the upcoming WORLDSymposium 2022 Conference,…